Literatur
Schmidt E, Zillikens D (2013) Pemphigoid diseases. Lancet 381:320–332. https://doi.org/10.1016/S0140-6736(12)61140-4
Hübner F, Recke A, Zillikens D et al (2016) Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J Invest Dermatol 136:2495–2498. https://doi.org/10.1016/j.jid.2016.07.013
Goletz S, Zillikens D, Schmidt E (2017) Structural proteins of the dermal-epidermal junction targeted by autoantibodies in pemphigoid diseases. Exp Dermatol 26:1154–1162. https://doi.org/10.1111/exd.13446
Ludwig RJ, Vanhoorelbeke K, Leypoldt F et al (2017) Mechanisms of autoantibody-induced pathology. Front Immunol 8. https://doi.org/10.3389/fimmu.2017.00603
Varpuluoma O, Försti A‑K, Jokelainen J et al (2018) Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study. J Invest Dermatol 138:1659–1661. https://doi.org/10.1016/j.jid.2018.01.027
Siegel J, Totonchy M, Damsky W et al (2018) Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2018.07.008
Kridin K, Ludwig RJ (2018) The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med 5. https://doi.org/10.3389/fmed.2018.00220
Försti A‑K, Huilaja L, Schmidt E, Tasanen K (2017) Neurological and psychiatric associations in bullous pemphigoid-more than skin deep? Exp Dermatol 26:1228–1234. https://doi.org/10.1111/exd.13401
Bech R, Kibsgaard L, Vestergaard C (2018) Comorbidities and treatment strategies in bullous pemphigoid: an appraisal of the existing literature. Front Med 5. https://doi.org/10.3389/fmed.2018.00238
Holtsche MM, Zillikens D, Schmidt E (2018) Mucous membrane pemphigoid. Hautarzt 69:67–83. https://doi.org/10.1007/s00105-017-4089-y
Schmidt E, della Torre R, Borradori L (2012) Clinical features and practical diagnosis of bullous pemphigoid. Immunol Allergy Clin North Am 32:217–232. https://doi.org/10.1016/j.iac.2012.04.002
Schulze F, Kasperkiewicz M, Zillikens D, Schmidt E (2013) Bullous pemphigoid. Hautarzt 64:931–943. https://doi.org/10.1007/s00105-013-2599-9 (quiz 944–945)
Schmidt E, Zillikens D (2011) The diagnosis and treatment of autoimmune blistering skin diseases. Dtsch Arztebl Int 108:399–405. https://doi.org/10.3238/arztebl.2011.0405
van Beek N, Zillikens D, Schmidt E (2018) Diagnostik blasenbildender Autoimmundermatosen. J Dtsch Dermatol Ges 16:1077–1092. https://doi.org/10.1111/ddg.13637_g
Schmidt E, Goebeler M, Hertl M et al (2015) S2k-Leitlinie zur Diagnostik des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoids: Diagnostik Pemphigus und bullöses Pemphigoid. J Dtsch Dermatol Ges 13:713–727. https://doi.org/10.1111/ddg.40_12612
Vodegel RM, Jonkman M, Pas HH, De Jong MCJM (2004) U‑serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol 151:112–118. https://doi.org/10.1111/j.1365-2133.2004.06006.x
Meijer JM, Atefi I, Diercks GFH et al (2018) Serration pattern analysis for differentiating epidermolysis bullosa acquisita from other pemphigoid diseases. J Am Acad Dermatol 78(4):754–759.e6. https://doi.org/10.1016/j.jaad.2017.11.029
van Beek N, Rentzsch K, Probst C et al (2012) Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet J Rare Dis 7:49. https://doi.org/10.1186/1750-1172-7-49
Sticherling M, Franke A, Aberer E et al (2017) An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol 177:1299–1305. https://doi.org/10.1111/bjd.15649
Williams HC, Wojnarowska F, Kirtschig G et al (2017) Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 389:1630–1638. https://doi.org/10.1016/S0140-6736(17)30560-3
Hübner F, Kasperkiewicz M, Knuth-Rehr D et al (2018) Adjuvant treatment of severe/refractory bullous pemphigoid with protein A immunoadsorption. J Dtsch Dermatol Ges 16:1109–1118. https://doi.org/10.1111/ddg.13642
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
M. Witte, E. Schmidt und R. Ludwig geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren. Für Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, über die Patienten zu identifizieren sind, liegt von ihnen und/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.
The supplement containing this article is not sponsored by industry.
Additional information
Redaktion
E. von Stebut, Köln
Redaktionelle Mitarbeit
R. Eming, Marburg
P. Moinzadeh, Köln
Rights and permissions
About this article
Cite this article
Witte, M., Schmidt, E. & Ludwig, R. 85/m mit Blasen am gesamten Integument. Hautarzt 69 (Suppl 2), 183–188 (2018). https://doi.org/10.1007/s00105-018-4291-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00105-018-4291-6